Advances in anti-fungal therapies

Waterer, Grant

doi:10.1007/s11046-021-00560-2

Cited by 14 publications

(7 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rising proportion of the community in Western countries with induced immune deficiencies caused by immunomodulatory therapies and their expanding indications is gradually increasing the burden of fungal diseases. Equally, unlike anti-bacterial therapies, which have exceptionally good response rates in sensitive pathogens, antifungal therapies are not as efficacious, due to poor host immunity, innate fungal properties and drug dosing limitations [52]. Moreover, drugs administered by the enteral or parenteral routes need to reach the blood circulation to be distributed to all apparatus and act on the infected site.…”

Section: Unmet Needs In Fungal Infectionsmentioning

confidence: 99%

Retinoids in Fungal Infections: From Bench to Bedside

et al. 2021

View full text Add to dashboard Cite

Retinoids—a class of chemical compounds derived from vitamin A or chemically related to it—are used especially in dermatology, oncohematology and infectious diseases. It has been shown that retinoids—from their first generation—exert a potent antimicrobial activity against a wide range of pathogens, including bacteria, fungi and viruses. In this review, we summarize current evidence on retinoids’ efficacy as antifungal agents. Studies were identified by searching electronic databases (MEDLINE, EMBASE, PubMed, Cochrane, Trials.gov) and reference lists of respective articles from 1946 to today. Only articles published in the English language were included. A total of thirty-nine articles were found according to the criteria. In this regard, to date, In vitro and In vivo studies have demonstrated the efficacy of retinoids against a broad-spectrum of human opportunistic fungal pathogens, including yeast fungi that normally colonize the skin and mucosal surfaces of humans such as Candida spp., Rhodotorula mucilaginosa and Malassezia furfur, as well as environmental moulds such as Aspergillus spp., Fonsecae monofora and many species of dermatophytes associated with fungal infections both in humans and animals. Notwithstanding a lack of double-blind clinical trials, the efficacy, tolerability and safety profile of retinoids have been demonstrated against localized and systemic fungal infections.

show abstract

Section: Unmet Needs In Fungal Infectionsmentioning

confidence: 99%

Retinoids in Fungal Infections: From Bench to Bedside

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In the future, ibrexafungerp may be used to treat a variety of fungal infections, including those attributed to resistant organisms, and it may be use alone or in combination with other drugs to treat a variety of invasive fungal pathogens [ 12 , 46 ]. We do not yet know the full potential of this novel antifungal agent, but FDA approval in June 2021 serves as an important milestone.…”

Section: Future Directionsmentioning

confidence: 99%

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp

McCarthy

2021

Drugs R D

View full text Add to dashboard Cite

On 2 June, 2021, the US Food and Drug Administration approved ibrexafungerp (formerly MK-3118 and SCY-078) for the treatment of vulvovaginal candidiasis, also known as vaginal yeast infection. Ibrexafungerp is the first drug approved in a novel antifungal class in more than two decades, and the Food and Drug Administration's decision was based on positive results from two pivotal phase III studies in which oral ibrexafungerp proved both safe and effective in patients with vulvovaginal candidiasis. The decision was also based on substantial preclinical and clinical work in both the pharmacokinetics and pharmacodynamics of ibrexafungerp. This paper reviews that research and looks ahead to explore how this novel antifungal agent may be used in the future to address the expanding problem of drug-resistant mycotic infections.

show abstract

“… 38 In this review, we elucidate contemporary strides in the synthetic methodology for the synthesis of thiazolyl-pyrazoline and thiazolyl-pyrazole hybrids employing phenacyl bromides as an emerging precursor. The resulting hybrids exhibit diverse pharmaceutical applications such as anticancer, 39 antibacterial, 40 antiinflammatory, 41 antifungal, 42 antitubercular, 43 anticonvulsant, 44 antioxidant, 45 antiviral, 46 etc. ( Figure 3 ).…”

Section: Introductionmentioning

confidence: 99%

Development in the Synthesis of Bioactive Thiazole-Based Heterocyclic Hybrids Utilizing Phenacyl Bromide

Kumari,

Dhillon,

Rani

et al. 2024

ACS Omega

View full text Add to dashboard Cite

Heterocyclic hybrid frameworks represent a burgeoning domain within the realms of drug discovery and medicinal chemistry, attracting considerable attention in recent years. Thiazole pharmacophore fragments, inherent in natural products such as peptide alkaloids, metabolites, and cyclopeptides, have demonstrated a broad spectrum of pharmacological potentials. Given their profound biological significance, a plethora of thiazole-based hybrids have been synthesized through the conjugation of thiazole moieties with bioactive pyrazole and pyrazoline fragments. This review systematically presents a compendium of robust methodologies for the synthesis of thiazole-linked hybrids, employing the (3 + 2) heterocyclization reaction, specifically the Hantzsch-thiazole synthesis, utilizing phenacyl bromide as the substrate. The strategic approach of molecular hybridization has markedly enhanced drug efficacy, mitigated resistance to multiple drugs, and minimized toxicity concerns. The resultant thiazole-linked hybrids exhibit a myriad of medicinal properties viz. anticancer, antibacterial, anticonvulsant, antifungal, antiviral, and antioxidant activities. This compilation of methodologies and insights serves as a valuable resource for medicinal chemists and researchers engaged in the design of novel thiazole-linked hybrids endowed with therapeutic attribute.

show abstract

Advances in anti-fungal therapies

Cited by 14 publications

References 67 publications

Retinoids in Fungal Infections: From Bench to Bedside

Retinoids in Fungal Infections: From Bench to Bedside

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp

Development in the Synthesis of Bioactive Thiazole-Based Heterocyclic Hybrids Utilizing Phenacyl Bromide

Contact Info

Product

Resources

About